{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:34:05Z","timestamp":1790674445715,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T00:00:00Z","timestamp":1453766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001348","name":"Agency for Science, Technology and Research","doi-asserted-by":"publisher","award":["SPF2012\/005"],"award-info":[{"award-number":["SPF2012\/005"]}],"id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"publisher","award":["SPF2012\/005"],"award-info":[{"award-number":["SPF2012\/005"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.expneurol.2016.01.019","type":"journal-article","created":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T15:32:20Z","timestamp":1453822340000},"page":"4-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease"],"prefix":"10.1016","volume":"278","author":[{"given":"Marta","family":"Garcia-Miralles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolene","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza","family":"Ferrari Bardile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang Juin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester L.","family":"Drum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel Yanping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud A.","family":"Pouladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2016.01.019_bb0005","doi-asserted-by":"crossref","first-page":"8608","DOI":"10.1523\/JNEUROSCI.5110-12.2013","article-title":"Huntingtin mediates anxiety\/depression-related behaviors and hippocampal neurogenesis","volume":"33","author":"Ben M'Barek","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0010","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.tins.2007.12.006","article-title":"MAOA and the neurogenetic architecture of human aggression","volume":"31","author":"Buckholtz","year":"2008","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fnsys.2011.00061","article-title":"In vivo dopamine efflux is decreased in striatum of both fragment (R6\/2) and full-length (YAC128) transgenic mouse models of Huntington's disease","volume":"5","author":"Callahan","year":"2011","journal-title":"Front. Syst. Neurosci."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0020","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1098\/rstb.1999.0449","article-title":"Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease","volume":"354","author":"Cha","year":"1999","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0025","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fnins.2013.00114","article-title":"Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility","volume":"7","author":"Chen","year":"2013","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0030","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/npp.2011.128","article-title":"Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease","volume":"36","author":"Chiu","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.expneurol.2016.01.019_bb0035","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","article-title":"Identification of genetic factors that modify clinical onset of Huntington's disease","volume":"162","author":"Consortium","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.expneurol.2016.01.019_bb0040","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0149-7634(85)90030-2","article-title":"Exploratory behavior models of anxiety in mice","volume":"9","author":"Crawley","year":"1985","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0045","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrd1825","article-title":"The ascent of mouse: advances in modelling human depression and anxiety","volume":"4","author":"Cryan","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0050","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.neubiorev.2005.03.009","article-title":"The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice","volume":"29","author":"Cryan","year":"2005","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0055","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fneur.2013.00081","article-title":"A tale of two maladies? Pathogenesis of depression with and without the Huntington's disease gene mutation","volume":"4","author":"Du","year":"2013","journal-title":"Front. Neurol."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0060","first-page":"112","article-title":"Monoamine oxidases in major depressive disorder and alcoholism","volume":"6","author":"Duncan","year":"2012","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0065","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2014.02.010","article-title":"Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release","volume":"143","author":"Finberg","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JHD-140134","article-title":"Epigenetic mechanisms involved in Huntington's disease pathogenesis","volume":"4","author":"Glajch","year":"2015","journal-title":"J. Huntingtons Dis."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0075","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pnpbp.2013.04.009","article-title":"Monoamine neurocircuitry in depression and strategies for new treatments","volume":"45","author":"Hamon","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.expneurol.2016.01.019_bb0080","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddt203","article-title":"Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington's disease","author":"Hult Lundh","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0085","first-page":"310","article-title":"Overview of serotonin syndrome","volume":"24","author":"Iqbal","year":"2012","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.expneurol.2016.01.019_bb0090","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.neuroscience.2013.01.071","article-title":"Changes in brainstem serotonergic and dopaminergic cell populations in experimental and clinical Huntington's disease","volume":"238","author":"Jahanshahi","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2016.01.019_bb0095","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s00018-009-0055-x","article-title":"Depression and antidepressants: molecular and cellular aspects","volume":"66","author":"Lanni","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0100","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(73)90844-1","article-title":"Serotonin, lithium, and Huntington's chorea","volume":"2","author":"Manyam","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.expneurol.2016.01.019_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018336","article-title":"Altered dopamine and serotonin metabolism in motorically asymptomatic R6\/2 mice","volume":"6","author":"Mochel","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2016.01.019_bb0110","article-title":"Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression","author":"Naoi","year":"2015","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0115","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrn1970","article-title":"Enriched environments, experience-dependent plasticity and disorders of the nervous system","volume":"7","author":"Nithianantharajah","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0120","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1007\/s12035-014-8974-4","article-title":"Inhibition of excessive monoamine oxidase A\/B Activity protects against stress-induced neuronal death in Huntington disease","volume":"52","author":"Ooi","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0125","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/hmg\/ddn385","article-title":"Altered serotonin receptor expression is associated with depression-related behavior in the R6\/1 transgenic mouse model of Huntington's disease","volume":"18","author":"Pang","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0130","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1176\/jnp.17.4.496","article-title":"Depression and stages of Huntington's disease","volume":"17","author":"Paulsen","year":"2005","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0135","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/brain\/awg119","article-title":"Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study","volume":"126","author":"Pavese","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2016.01.019_bb0140","first-page":"356","article-title":"Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers","volume":"37","author":"Pavese","year":"2010"},{"key":"10.1016\/j.expneurol.2016.01.019_bb0145","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0165-0270(85)90031-7","article-title":"Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat","volume":"14","author":"Pellow","year":"1985","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.expneurol.2016.01.019_bb0150","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/brain\/awp006","article-title":"Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin","volume":"132","author":"Pouladi","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2016.01.019_bb0155","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.nbd.2012.06.026","article-title":"NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease","volume":"48","author":"Pouladi","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0160","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1093\/hmg\/dds037","article-title":"Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice","volume":"21","author":"Pouladi","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0165","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrn3570","article-title":"Choosing an animal model for the study of Huntington's disease","volume":"14","author":"Pouladi","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022133","article-title":"Sexually dimorphic serotonergic dysfunction in a mouse model of Huntington's disease and depression","volume":"6","author":"Renoir","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2016.01.019_bb0175","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3233\/JHD-120039","article-title":"Antidepressant-like effect of the norepinephrine\u2013dopamine reuptake inhibitor bupropion in a mouse model of Huntington's disease with dopaminergic dysfunction","volume":"1","author":"Renoir","year":"2012","journal-title":"J. Huntingtons Dis."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0180","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pbb.2014.10.004","article-title":"Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease","volume":"127","author":"Renoir","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0185","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.brainres.2010.11.020","article-title":"Up-regulation of the isoenzymes MAO-A and MAO-B in the human basal ganglia and pons in Huntington's disease revealed by quantitative enzyme radioautography","volume":"1370","author":"Richards","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0190","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/acn3.214","article-title":"A systems-level \u201cmisunderstanding\u201d: the plasma metabolome in Huntington's disease","volume":"2","author":"Rosas","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0195","doi-asserted-by":"crossref","first-page":"191","DOI":"10.31887\/DCNS.2007.9.2\/arosenblatt","article-title":"Neuropsychiatry of Huntington's disease","volume":"9","author":"Rosenblatt","year":"2007","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0200","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s004390050816","article-title":"A functional polymorphism in the monoamine oxidase A gene promoter","volume":"103","author":"Sabol","year":"1998","journal-title":"Hum. Genet."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0205","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4161\/epi.21976","article-title":"Evidence that the methylation state of the monoamine oxidase A (MAOA) gene predicts brain activity of MAO A enzyme in healthy men","volume":"7","author":"Shumay","year":"2012","journal-title":"Epigenetics"},{"key":"10.1016\/j.expneurol.2016.01.019_bb0210","first-page":"249","article-title":"Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease","volume":"41","author":"Simpson","year":"2011"},{"key":"10.1016\/j.expneurol.2016.01.019_bb0215","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0220","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/jnp.2007.19.4.441","article-title":"Psychopathology in verified Huntington's disease gene carriers","volume":"19","author":"van Duijn","year":"2007","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0225","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nprot.2007.44","article-title":"The use of the elevated plus maze as an assay of anxiety-related behavior in rodents","volume":"2","author":"Walf","year":"2007","journal-title":"Nat. Protoc."},{"issue":"Suppl. 1","key":"10.1016\/j.expneurol.2016.01.019_bb0230","doi-asserted-by":"crossref","first-page":"S287","DOI":"10.1038\/sj.bjp.0706464","article-title":"Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness","volume":"147","author":"Youdim","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2016.01.019_bb0235","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","article-title":"The therapeutic potential of monoamine oxidase inhibitors","volume":"7","author":"Youdim","year":"2006","journal-title":"Nat. Rev. Neurosci."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488616300188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488616300188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T14:53:52Z","timestamp":1617461632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488616300188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":47,"alternative-id":["S0014488616300188"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2016.01.019","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2016.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}